PIPELINE

PIPELINE

Leveraging its internal drug discovery and development expertise, Terns is building a robust pipeline of therapeutics that target unmet medical needs in underserved markets. Our goal is to adopt global or region-specific development strategies for advancing new clinical-stage therapeutics, and to ultimately make them globally available to patients.

NASH

  • Discovery
  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
40% Complete (success)
TERN-101 (FXR Agonist) - EU
45% Complete
TERN-101 (FXR Agonist) - China
45% Complete
TERN-201 (SSAO Inhibitor)
45% Complete
Undisclosed Target 1
45% Complete
Undisclosed Target 2
45% Complete
Undisclosed Target 3

ONCOLOGY

  • Discovery
  • Pre-clinical
  • Phase 1
  • Phase 2
  • Phase 3
45% Complete
HCC Undisclosed Target 1
45% Complete
GI Undisclosed Target 2
45% Complete
CML Undisclosed Target 3

Farnesoid X Receptor (FXR) Agonism and TERN-101

FXR is a nuclear receptor expressed in high amounts in the liver and small intestine. Bile acids (BA) are natural ligands of FXR, and their binding with and activation of FXR is critical to the regulation of cellular pathways that modulate BA synthesis, lipid metabolism, inflammation and fibrosis. It is believed by many in the scientific community that FXR agonism and activation has potential as a new treatment modality for nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). TERN-101 is a potent non-bile acid FXR agonist being developed as a therapeutic for NASH.

Semicarbazide-Sensitive Amine Oxidase (SSAO) Inhibition and TERN-201

SSAO, also known as VAP-1 (Vascular Adhesion Protein-1), is a dual-function amine oxidase which promotes recruitment of white blood cells in the liver, and can result in increased oxidative stress, inflammation and hepatic fibrosis. The level of surface SSAO is upregulated in the vasculature of inflamed tissues, and soluble SSAO levels are elevated in patients with NASH. Inhibition of SSAO is believed to have therapeutic benefit for the treatment of NAFLD, NASH and other chronic fibrotic liver diseases. TERN-201 is a potent SSAO inhibitor which may provide an additional treatment mechanism for NASH by reducing oxidative stress and recruitment of white blood cells to the liver.

About NASH

Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis and eventually liver cancer or liver failure. Global rates of NAFLD and NASH are increasing rapidly, in tandem with rising rates of obesity. It is estimated that 15 percent of the Chinese adult population has NAFLD. Of those patients, an estimated 20 percent will develop NASH. There is currently no approved medication for the treatment of NASH.